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Purpose: To evaluate therapeutic effects and usefulness of a combination treatment of intravitreal injection 
of triamcinolone acetonide (IVTA) and panretinal photocoagulation (PRP) in patients with clinically significant 
macular edema secondary to proliferative diabetic retinopathy (PDR).
Methods: Visual acuity test, fundoscopy, fluorescein angiography, and optical coherence tomography (OCT) 
were taken in 20 patients (20 eyes) of macular edema and PDR. A combination of intravitreal injection of 
triamcinolone acetonide and PRP was performed in 10 patients (10 eyes) and a combination of focal or grid 
laser photocoaqulation and PRP in the remaining 10 eyes. The postoperative outcomes were compared 
between the two combination treatments by best corrected visual acuity (BCVA), tonometry, fluorescein 
angiography, and OCT at 2 weeks, 1, 2, and 3 months.
Results: Average BCVA (log MAR) significantly improved from preoperative 0.56±0.20 to 0.43±0.08 at 1 
month (P=0.042) and it was maintained until 3 months after a combination of IVTA and PRP in 10 eyes 
(P=0.007). The thickness of fovea decreased from average 433.3±114.9 μm to average 279.5±34.1 μm at 
2 weeks after combined treatment of IVTA and PRP (P=0.005), which was significantly maintained until 3 
months, but there was a transient visual disturbance and no significant difference in thickness of the fovea 
before and after treatment in the groups with PRP and focal or grid laser photocoagulation.
Conclusions: A combination of IVTA and PRP might be an effective treatment modality in the treatment of 
macular edema and PDR and prevent the subsequent PRP-induced macular edema result in visual 
dysfunction. In combination with PRP, IVTA might be more effective than focal or grid laser photocoagulation 
and PRP for reducing diabetic macular edema and preventing aggravation of macular edema without 
transient visual disturbance in patients requiring immediate PRP. 
Korean Journal of Ophthalmology 21(1):11-17, 2007
Key Words: Intravitreal triamcinolone acetonide injection, Macular edema, Panretinal photocoagulation, 
Proliferative diabetic retinopathy
Diabetic macular edema is the leading cause of decrease 
in visual acuity and may frequently lead to irreversible 
changes in visual acuity. Focal or grid laser photocoagulation 
has been performed for diabetic macular edema, but it has 
been known that laser photocoagulation requires a con-
siderable time for recovery of macular edema and moderate 
visual loss can be prevented with little improvement of visual 
acuity only in 50% of patients.
1-4 Panretinal photocoagulation 
(PRP) is an effective method to prevent neovascularization 
and progression of proliferative diabetic retinopathy (PDR), 
but aggravation of macular edema with decrease in visual 
acuity may occur in diabetic retinopathy accompanied by 
macular edema after PRP.
5-9 When PRP is performed after 
focal or grid laser therapy for macular edema, moderate 
visual loss can be reduced, but the timing of PRP may be 
delayed because this procedure should be performed after 
sufficient stabilization of macular edema.
1,5,8
Intravitreal injection of triamcinolone acetonide (IVTA) is 
effective in the elimination of macular edema and im-
provement of visual acuity, especially in diabetic macular 
edema unresponsive to laser therapy, so it has recently been 
in wide use.
10,11 It has been suggested that alleviation of 
macular edema by triamcinolone acetonide (TA) may prevent 
aggravation of macular edema secondary to PRP. 
This study was designed to evaluate therapeutic effects and 
usefulness of a combination of a PRP combined with IVTA Kor J Ophthalmol Vol.21, No.1, 2007
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and a PRP combined with focal or grid laser photo-
coagulation in order to maximize the effect of laser 
photocoagulation and reduce macular edema, which may be 
aggravated after PRP, in patients with both clinically 
significant macular edema (CSME) and PDR requiring 
immediate PRP.
Materials and Methods
Anterior segment examination, best-corrected visual acuity 
(BCVA), tonometry, and fundus examination were taken in 
patients with CSME secondary to diabetic retinopathy. The 
severity level of diabetic retinopathy was determined as 
defined in a diabetic retinopathy study based on the fundus 
examination and fluorescein angiography by the same 
examiner (J.K.C.). CSME was evaluated by slit lamp bio-
microscopy using a noncontact lens, as defined by the early 
treatment diabetic retinopathy study and the extent were 
assessed with fluorescein angiography and optical coherence 
tomography (OCT; Zeiss-Humphrey, Dubin, CA). This study 
included patients with PDR who required PRP and excluded 
patients with previous intraocular operations such as laser 
photocoagulation or IVTA, glaucoma, and cataract causing 
decrease in visual acuity. In addition, to eliminate the effects 
of systemic conditions, patients who had systolic and 
diastolic blood pressures of higher than 130 and 80 mmHg 
respectively, regardless of medication at each visit, and those 
who were diagnosed diabetic nephropathy by internal me-
dicine specialist were excluded from this study. Glycated 
hemoglobin levels just before and 3 months after treatment 
were measured and any patients with levels exceeding 8.0% 
were excluded from the study. All medical procedures 
followed the tenets of the Declaration of Helsinki with the 
approval of our Institutional Review Broad. All patients who 
gave written consent to this study after complete description 
of the procedure were randomly allotted. Patients in 
combined treatment group underwent IVTA with PRP, and 
patients in laser treatment group underwent focal or grid laser 
therapy with PRP. At 2 weeks, 1, 2, and 3 months 
postoperatively, the absence or presence of complications was 
confirmed by anterior segment examination, fundoscopy, and 
tonometry, and the outcomes were measured with BCVA, 
fluorescein angiography and foveal thickness by OCT.
TA (Tamceton; 40 mg/1 ml, Hanall Pharmaceutical, Seoul, 
Korea) was injected into the vitreous body at the operating 
theater at the day of surgery after PRP was performed at the 
lower half of the retina. Since several reports have shown 
that the vehicle of TA may have toxicity to the intraocular 
tissue and not a few studies have suggested that TA should 
be injected after discarding its vehicle,
12,13 we prepared TA 
in the following manner. A vial of TA was set aside until 
the TA was submerged to the bottom, and the solvent was 
discarded. Then, the TA was mixed with balanced salt 
solution (BSS), to make the final volume to 1 ml. From the 
solution, 0.1 ml was placed in a 1 ml tuberculin syringe and 
the syringe was placed upside down for 10 minutes to obtain 
the secondary precipitate. After sterilization of peripalpebral 
region and conjunctiva with 10% and 5% povidone-iodine 
solution, proparacaine was instilled into the conjunctiva for 
topical anesthesia. To minimize the volume effect only the 
sedimented TA (4 mg) with minimal BSS was injected into 
the vitreous body until TA crystals disappeared completely 
at the needle hub (about 0.03~0.05 ml). It was injected 3.0 
to 3.5 mm posteriorly from the corneal limbus at five 
o’clock using a 30 gauge needle.
The injection site was compressed using a cotton pledget 
for 20 seconds without anterior chamber paracentesis. It was 
confirmed that there were no complications such as retinal 
tear and vitreous hemorrhage by fundoscopy using an indirect 
ophthalmoscope after IVTA. Laser photocoagulation was 
repeated at the upper half of the retina 2 weeks later.
After retinal photocoagulation was performed at the pri-
mary site in combination with focal or grid laser therapy, 
PRP was conducted three times at 1 week intervals. Two 
patients underwent grid laser photocoagulation according to 
the ETDRS guide-lines. Photocoagulation in spots of 100 to 
200 μm diameter in the macular area, at a distance of one 
to two spots from one to another, in concentric lines, with 
an exposure time of 0.2~0.5 seconds, was performed, with 
sparing of the central area. Eight patients with micro-
aneurysms ranging from 500 to 3000 μm from the center of 
the macula were treated with focal laser photocoagulation. 
The spot size, power, and time setting were 100 μm, 150 
mW, and 0.1 seconds. Panretinal scatter photocoagulation in 
both groups were performed with the size of the spots on the 
retina was 500 μm, and the duration of the application was 
0.15 to 0.2 seconds. A krypton red laser was used, resulting 
in gray retina. Each spot was produced by a 120 to 200 mW 
exposure. The total number of burns after complete sessions 
was 1574.3±41.7 in combined treatment group and 1595.7±
56.2 in laser treatment group (p=0.436). Topical anesthesia 
was used in all cases, and all patients were treated by the 
same ophthalmologist (K.S.C).
Foveal thickness was taken to calculate the averaged 
thickness in the central ring, 1000 μm in diameter, by means 
of the Fast Macular Thickness scan of OCT. BCVA was 
measured on a Snellen chart after refraction and correction. 
Analyses of BCVA were performed by converting Snellen 
visual acuity measurement to log minimum angle of 
resolution (logMAR) equivalents. Intraocular pressure was 
measured with a Goldman applanation tonometer.
The Mann-Whitney test and the Wilcoxon signed rank test 
were applied to compare the differences between the two 
groups and in the group respectively. The Kruskal 
Wallis test was used for comparison of three or more 
parameters.  P<0.05 was considered significant, and 
SPSS for Windows (SPSS Inc., Chicago, IL) was used 
for statistical analysis. KS Choi, et al. COMBINED TREATMENT OF IVTA AND PRP
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Fig. 1. Evaluation of mean foveal thickness and best corrected 
visual acuity after combined intravitreal injection of 
triamcinolone acetonid and panretinal photocoagulation.
: statistically significant difference between initial foveal 
thickness and each value, *: statistically significant difference 
between best corrected visual acuity before and after 
combination treatment.
 
Fig. 2. Changes of foveal thickness and best corrected visual 
acuity in patients treated with focal or grid laser 
photocoagulation and panretinal photocoagulation. *: statistically 
significant difference between best corrected visual acuity before 
and after laser treatment. The values of foveal thicknessare not 
significantly different from baseline.
Characteristic Combined treatment group (10 eyes) Laser treatment group (10 eyes) P value*
Age (years, mean±SD) 58.3±7.8 59.7±8.2 0.486
Duration of DM (months, mean±SD) 155.4±20.1 150.2±15.8 0.436
Glycated hemoglobin (%, mean±SD)
Before treatment 7.61±0.48
† 7.48±0.40
‡ 0.393
Three months after treatment 7.68±0.30
† 7.59±0.40
‡ 0.796
Severity level of PDR
Moderate 1 2
High risk 9 8
BCVA (logMAR, mean±SD) 0.56±0.20 0.46±0.14 0.315
Foveal thickness (μm, mean±SD) 433.3±114.9 328.7±34.2 0.052
Intraocular pressure (mmHg, mean±SD) 17.2±2.7 16.8±2.6 0.673
SD: standard deviation, DM: diabetes mellitus, PDR: proliferative diabetic retinopathy, BCVA: best corrected visual acuity, 
logMAR: 
log of minimum angle of resolution, *: statistical significance was tested by Mann-Whitney Test,
†:  p=0.975 by Wilcoxon 
Singed 
Ranks Test, 
‡: p=0.341 by Wilcoxon Singed Ranks Test.
Table 1. Baseline characteristics of two groups enrolled in the present study
Results
Ten patients (10 eyes) treated with combination treatment 
and 10 patients (10 eyes) treated with laser photocoagulation 
were enrolled for main outcome measurement. The baseline 
characteristics of the two groups are presented in Table 1.
In the group with a combination treatment of IVTA and 
PRP, postoperative thickness of the fovea decreased 
significantly to 279.5±34.1 (P=0.005), 257.0±47.2 (P=0.005), 
263.4±52.0 (P=0.007), and 259.7±43.1 μm (P=0.005) at 
2 weeks, 1, 2, and 3 months, respectively, as compared with 
preoperative thickness of the fovea (Table 2, Fig. 1). 
However, there was no significant difference in thickness of 
the fovea between the experimental time points (P>0.750). In 
the group with focal or grid laser photocoagulation and PRP, 
postoperative thickness of the fovea increased to 339.9±32.5 
and 333.8±28.1 μm at 2 weeks and 1 month, respectively, 
as compared with baseline thickness of the fovea without 
significant difference (P=0.139, and 0.798, respectively), and 
the macular edema began to decrease 2 months after 
treatment without significant difference (Table 2, Fig. 2). In 
the group with a combination treatment, BCVA did not 
change significantly at 2 weeks after surgery. However, it 
improved significantly at 1 month (P=0.042) and visual 
improvement was continued until 3 months (Fig. 1). In the 
group with laser photocoagulation, visual acuity decreased to 
0.50±0.13 (P=0.046), 0.47±0.11 (P=0.792), and 0.47±0.08 
(P=0.792) at 2 weeks, 1, and 2 months after treatment, 
respectively. A transient visual disturbance occurred at 2 
weeks then returned to initial visual acuity at 3 months after Kor J Ophthalmol Vol.21, No.1, 2007
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Foveal thickness in combined treatment group Foveal thickness in laser treatment group
Case
No. Base-line 2 wks 1 Mo 2 Mos 3 Mos Base-line 2 wks 1 Mo 2 Mos 3 Mos
1 350 300 280 275 300 300 338 372 327 352
2 452 300 304 310 320 299 289 279 280 280
3 353 268 326 370 324 294 338 331 307 316
4 346 241 245 218 224 385 377 375 355 324
5 320 252 195 215 223 301 314 311 316 307
6 294 215 224 220 213 338 344 348 362 339
7 582 305 178 201 225 347 348 326 291 298
8 485 324 285 278 235 357 355 335 355 329
9 577 294 278 280 284 298 301 323 287 298
10 574 296 255 267 249 368 395 338 325 309
Mea
n
(SD)
433.3±114.9 279.5*±34.1 257.0*±47.2 263.4*±52.0 259.7*±43.1 328.7±34.2 339.9
†±32.5 333.8
†±28.1 320.5
†±29.8 315.2
†±21.4
SD: standard deviation, Values are expressed in microns, *: each values were compared with base line foveal thickness, p<0.01 by 
Wilcoxon Singed Ranks Test, 
†: each values were compared with base line foveal thickness, p>0.1 by Wilcoxon Singed Ranks Test.
Table 2. Foveal thickness measured with optical coherence tomography in the combined (panretinal photo-
coagulation and intravitreal injection of triamcinolone acetonide) treated eyes before treatment and 2 weeks, 1, 2, 
3 months thereafter, photocoagulation only treatment group
Fig. 3. Fundus photographs (top), fluorescein angiograms 
(middle), and optical coherence tomography (bottom) of case 
7 in combination treatment group. (A) Findings of initial 
examination. (B) One month after combined intravitreal 
injection of triamcinolone acetonide and panretinal 
photocoagulation. Late-phase fluorescein angiogram showing 
the marked decreased amount of leaking on macula and 
perivascular area. Note the decreased foveal thickness as seen 
on the optical coherence tomography.
treatment (Fig. 2). The changes in intraocular pressure in the 
group with a combination treatment were 16.1±4.2, 17.3±
3.8, 16.9±5.7, and 16.6±5.4 mmHg at 2 weeks, 1, 2, and 
3 months after surgery, and the intraocular pressure did not 
exceed 21 mmHg. Complications such as endophthalmitis, 
retinal detachment, or vitreous hemorrhage did not occur 
in all patients.
In fluorescein angiography, the group with a combination 
treatment showed a decrease in the late-onset fluorescein leak 
in the macula and perivascular area (Fig. 3), whereas the 
group with laser photocoagulation exhibited only a slight 
decrease in the leak or an increase (Fig. 4).
In the group with a combination treatment, laser photoco-
agulation at the upper half of the vitreous was not disturbed 
by triamcimolone particles which were injected 2 weeks 
before laser photocoagulation since the particles were 
localized at the lower half of the retina.
Discussion
In diabetic retinopathy, diabetic macular edema occurs due 
to leak and accumulation of body fluid or plasma in the outer 
plexiform layer or inner nuclear layer which were induced by 
destruction of the inner blood retinal barrier due to micro-
aneurysm or capillaries damaged by hyperpermeability. This 
is one of the leading causes of decreased visual acuity in 
diabetic retinopathy along with vitreous hemorrhage. It is 
reported that macular edema occurs in 10% of patients with 
diabetic retinopathy, and the incidence becomes higher with 
increasing duration and severity of the disease.
1-4,14
It has been well known that PRP is effective in the pre-
vention of visual loss and neovascularization.
3,4,15,16 However, 
it is reported that PRP may cause visual loss, macular edema, KS Choi, et al. COMBINED TREATMENT OF IVTA AND PRP
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Fig. 4. Fundus photographs (top), fluorescein angiograms (middle),
and optical coherence tomography (bottom) of case 1 in laser 
treatment group. (A) Findings of initial examination. (B) One 
month after grid laser photocoagulation and panretinal 
photocoagulation. Late-phase fluorescein angiogram showing 
increased amount of fluid collection on macula. Note the increased
foveal thickness as seen on the optical coherence tomography in 
spite of laser treatment.
and aggravation of preexisting macular edema, and the visual 
loss due to PRP-induced macular edema occurs in 25% to 
43% of the patients.
6,7,16-19 These problems frequently make 
ophthalmologists hesitate to perform PRP in patients with 
both severe diabetic retinopathy and CSME, although the 
patients have disturbance of everyday life due to visual loss 
especially in patients with preexisting visual loss. 
Gardner et al
20 reported that postoperative aggravation of 
macular edema can be diminished by performing PRP in 
multiple stages. Aiello et al
21  advocated that it is advisable 
to perform PRP after macular edema is treated by focal or 
grid laser photocoagulation. However, the therapeutic effect 
of PRP is limited, and it is not recommended to delay PRP 
in high-risk PDR.
21,22 According to the results of Shimura et 
al
8, when PRP was performed four times at intervals of 1 to 
2 weeks on patients with nonproliferative diabetic reti-
nopathy or non-high-risk PDR, transient macular edema was 
developed in both the group treated at 1 week intervals (1 
week group) and the group treated at 2 week intervals (2 
week group), indicating that macular edema was more severe 
in 1 week group than in 2 week group and the maintenance 
rate of visual acuity at the first visit was lower in 1 week 
group (89%) than in 2 week group (92%). However, since 
laser photocoagulation at 2 week intervals requires a total of 
8 weeks and the outcomes after PRP are not evaluated yet 
in PDR patients with macular edema, it is thought to be not 
an advisable treatment modality.
In the present study, macular edema began to decrease 
from 2 weeks and was maintained until 3 months, and visual 
acuity began to improve without transient decrease in visual 
acuity from 1 month after surgery and was maintained until 
3 months in the group with a combination treatment.
In addition, there was no patient whose thickness of the 
fovea was aggravated again to the preoperative status at each 
experimental time point (2 weeks, 1, 2, and 3 months). The 
results from thickness of the macula before and after PRP 
were presented in patients with milder diabetic retinopathy 
(nonproliferative diabetic retinopathy or non-high-risk PDR 
without CSME) as compared to this study by Shimura et al
8, 
who reported that in 1 week group, thickness of the fovea 
increased 1.42 (±0.05) times more at 4 weeks after PRP 
than initial foveal thickness, and in 2 week group, it 
increased 1.16 (±0.03) times more at 7 weeks after PRP 
than initial foveal thickness. In this study, the results from 
the group with laser photocoagulation revealed that thickness 
of the fovea increased 1.034 times and 1.015 times more at 
2 weeks and 1 month after treatment, respectively, and 7 of 
10 eyes had aggravated macular edema at 2 weeks, six eyes 
at 1 month, and five eyes at 2 or 3 months after treatment. 
From these results, it is suggested that a combination of 
IVTA and PRP is effective in the treatment of diabetic 
macular edema and prevention of its aggravation after laser 
photocoagulation. A more important finding in this study was 
that there was no patient with aggravation of visual acuity 
after a combination treatment during the follow-up period. 
Shimura et al
9 reported that patients with normal visual acuity 
of 20/20 or more exhibited transient decrease in visual acuity 
in 4.7% of patients and persistent decrease in visual acuity 
of 2 lines or more in 10.9% of patients during the follow-up 
period of 6 months after PRP. They also reported that 
occurrence rate of macular edema with subsequent decrease 
in visual acuity was significantly higher in eyes with a 
greater parafoveal thickness (> 300 μm) before PRP. 
Although all patients with a combination treatment except 
one (case 6) had greater (> 300 μm) parafoveal thickness 
(401.7±41.5 μm) in the present study, there was no case of 
aggravation of macular edema or deterioration of visual 
acuity due to the treatment.
Complications of IVTA include cataract, elevated intra-
ocular pressure, choroidal hemorrhage, retinal detachment, 
and endophthalmitis.
7,23-25 They did not occurred in the group 
with combination treatment during the follow-up period of 3 
months.
After a combination treatment, late fluorescein angiographs 
exhibited decreased leak in the macular region, which was 
consistent with the result from OCT, and generalized 
degeneration of the newly formed vessels. On the grounds Kor J Ophthalmol Vol.21, No.1, 2007
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that TA is effective in suppressing neovascularization in an 
experimental setting and reducing synthesis of new vessels in 
the iris and choroid in a clinical setting, it is inferred that 
the inhibitory effect of both PRP and TA influence the 
degeneration of the newly formed blood vessels in PDR.
26-28 
Although the exact mechanism of aggravation of macular 
edema after PRP has not been elucidated yet, destruction of 
blood retinal barrier by laser therapy, which is one of the 
various retinal diseases causing macular edema and some 
cytokines, such as interleukin-6 and interleukin-8 related to 
tissue inflammation appears to contribute to its mechanism.
8,9 
TA inhibits blood retinal barrier damage induced by cyto-
kines or endothelial growth factor and is effective in the 
treatment of macular edema, which will explain our finding 
that occurrence of macular edema can be inhibited by 
stabilization of damaged blood retinal barrier.
29,30
In conclusion, the results of this study suggest that a com-
bination of PRP and IVTA may improve visual acuity 
through inhibition of macular edema induced by laser photo-
coagulation and have an inhibitory effect on degeneration of 
the newly formed blood vessels. TA seems to be synergistic 
with PRP. In combination with PRP, IVTA might be more 
effective than laser photocoagulation in reducing diabetic 
macular edema and preventing aggravation of macular edema 
and transient visual disturbance in patients requiring im-
mediate PRP. Although additional studies on prognosis and 
treatment outcomes are needed due to a small sample size 
and a short duration of follow-up in this study, the advantage 
of a combination treatment should not be ignored. A 
combination of PRP and IVTA would be expected to be used 
as a new treatment modality in patients with macular edema 
secondary to PDR requiring PRP.
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